Insulet Corporation Überblick
Branche: Healthcare Equipment & Supplies
Sektor: Healthcare
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the hand
Research-Überblick
Letztes Berichtsdatum 2026-08-05Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Insulet Corporation (PODD): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.
- Börsennotierung
- PODD · Nasdaq · MIC XNAS
- Land
- United States
- Handelswährung
- USD
- Branche
- Healthcare Equipment & Supplies
- Finanzdaten
- Jahres- und Zwischenabschlüsse verfügbar
- Letzte Primärquelle
- SEC EDGAR · veröffentlicht 2026-08-05
Primärquellen
- Letzter Bericht · SEC EDGAR Veröffentlicht 2026-08-05
- Registrierungsdokument
Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.
Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Insulet Corporation für einen nachvollziehbaren Research-Prozess ein.
Score
Veröffentlichte Ergebnisse
Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.
Quarterly result summary
Revenue was $801.7M (+23.5% YoY). Operating income was $129.7M. Net income was $95M.
Revenue
$801.7M
+23.5% YoY
Operating income
$129.7M
reported
Net income
$95M
reported
Adjusted EBITDA
$199.8M
+702% YoY
Was sich verändert hat
- Revenue +23.5% YoY to $801.7M.
- Adjusted EBITDA +702% YoY to $199.8M.
- Operating income of $129.7 million, or 16.2% of revenue, down 250 basis points over prior year.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Bericht öffnen
Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.
Weitere aktuelle Ergebnisunterlagen
SEC filing
10-Q
Aug 05, 2026
SEC filing
8-K
Aug 05, 2026
SEC filing
10-Q
May 06, 2026
SEC filing
8-K
May 06, 2026
Earnings release
Earnings release
May 06, 2026
SEC filing
10-K
Feb 18, 2026
SEC filing
8-K
Feb 18, 2026
Earnings release
Earnings release
Feb 18, 2026
SEC filing
10-Q
Nov 06, 2025
SEC filing
8-K
Nov 06, 2025
Earnings release
Earnings release
Nov 06, 2025
Geprüfte Signal-Evidenz
Aktuelle Nachrichten
Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law
Headline from GlobeNewswire: PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law.
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Headline from PR Newswire: Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit.
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law
Headline from GlobeNewswire: PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law.
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Headline from PR Newswire: Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit.
Insulet Deadline: PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit
Headline from PR Newswire: Insulet Deadline: PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit.
Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
Headline from Zacks Investment Research: Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
Gewinn je Aktie
Score 3.00/5
Insulet Corporation boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Healthcare Equipment & Supplies industry
, AmerisourceBergen
, NuVasive Inc
, Computer Programs and Systems Inc
are companies with high ratings.
Eigenkapitalrendite
Score 3.22/5
Insulet Corporation stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Nettomarge
Score 4.42/5
Insulet Corporation
commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Verschuldung
Score 1.33/5
Insulet Corporation
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Finanzberichte
Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.
Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.
Finanzkennzahlen
Jährlich
Quartalsweise
Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen